The IONA Nx uses a new fetal fraction enrichment step with the Yourgene QS250 instrument, which enriches fetal fraction by two-fold, reducing the need for as much sequencing—making it a more cost effective NIPT workflow.
The IVD controls each provide a complete validation for extraction, amplification, and detection within a molecular assay.
OnkoSight Advanced NGS testing provides targeted gene content that is aligned with the latest National Comprehensive Cancer Network (NCCN) and World Health Organization (WHO) guideline recommendations, to provide insights into many of the most common cancer types.
The panel includes both RNA-based and DNA-based viruses in one kit with 41,047 nucleic acid probes. It allows researchers to separate COVID-19 symptoms from those of other respiratory illnesses, both influenza- and non-influenza-related.
The direct-to-patient collection kit must still be ordered by a licensed healthcare provider and clinicians can visit the online GeneSight portal to request that a kit be sent directly to the patient.
Sema4 Signal is a family of products and services providing data-driven precision oncology solutions with advanced analytics, digital tools, and exome-based somatic and hereditary cancer genomic tests.
Delivered as a comprehensive Software-As-A-Service (SaaS) solution, the LabVantage COVID-19 Biobanking Accelerator requires no infrastructure investment.
The PD-L1 assay and the AccuCyte-CyteFinder system processes a single tube of blood to cells for CTC enumeration and PD-L1 biomarker expression analysis, and to plasma for optional cfDNA analysis.
COVID-19 Compass is based on CDC guidelines, best clinical practices, illness severity, and risk factors such as age, gender, location, potential exposure and pre-existing health conditions.
EsoGuard is designed to facilitate the diagnosis of Barrett’s Esophagus (BE) and related precursors to highly lethal esophageal adenocarcinoma (EAC).